Monograph Details

Hematology > Thromboembolic disorders
TNKASE
Manufacturer
Genentech, Inc.
Legal Classification
Rx
Pharmacological Class
Tissue plasminogen activator (tPA).
Generic Name
Tenecteplase 50mg/vial; lyophilized pwd for IV inj after reconstitution.
Indications
To reduce mortality associated with acute myocardial infarction (AMI).
Children
Not recommended.
Adults
Start treatment soon after onset of AMI symptoms. Give as single IV bolus over 5 seconds. <60kg: 30mg; ≥60kg–<70kg: 35mg; ≥70kg–<80kg: 40mg; ≥80kg–<90kg: 45mg; ≥90kg: 50kg. Max: 50mg.
Contraindications
Active internal bleeding. History of cerebrovascular accident. Intracranial or intraspinal surgery or trauma within 2 months. Intracranial neoplasm, arteriovenous malformation, or aneurysm. Bleeding diathesis. Severe uncontrolled hypertension.
Precautions
Avoid noncompressible arterial puncture, internal jugular and subclavian venous puncture, IM injections and nonessential handling of patient during treatment. Increased bleeding risk at puncture sites; minimize arterial and venous punctures. Increased risk of complications with recent major surgery, cerebrovascular disease, GI or GU bleeding, recent trauma, hypertension (systolic BP ≥180mm Hg and/or diastolic BP ≥110mm Hg), left heart thrombus, acute pericarditis, endocarditis, hemostatic defects, hepatic dysfunction, pregnancy, hemorrhagic ophthalmic conditions, septic thrombophlebitis, elderly. Pregnancy (Cat.C). Nursing mothers.
Interactions
Increased bleeding risk with heparin, vitamin K antagonists, aspirin, dipyridamole, GP IIb/IIIa inhibitors. May interfere with coagulation tests.
Adverse Reactions
Bleeding, hypersensitivity reactions, cardiogenic shock, arrhythmias, AV block, pulmonary edema, heart failure, cardiac arrest, recurrent MI, myocardial rupture, cardiac tamponade, pericarditis, pericardial effusion, mitral regurgitation, thromboembolism, electromechanical dissociation, nausea, vomiting, hypotension, fever; cholesterol embolism.
How Supplied
Vial—1 (w. diluent, supplies)